Production of recombinant β-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta

Applied and Environmental Microbiology

Volumn 73, Issue 15, 2007, Pages 4805-4812

  Akeboshi, Hiromi ^a,b   Chiba, Yasunori ^a,b   Kasahara, Yoshiko ^a   Takashiba, Minako ^a   Takaoka, Yuki ^a   Ohsawa, Mai ^b,c   Tajima, Youichi ^b,c   Kawashima, Ikuo ^b,c   Tsuji, Daisuke ^b,d   Itoh, Kohji ^b,d   Sakuraba, Hitoshi ^b,c   Jigami, Yoshifumi ^a,b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME REPLACEMENT THERAPY (ERT); GANGLIOSIDES; MANNOSE-6-PHOSPHATE (M6P);

CELLS; DISEASE CONTROL; ELECTROPHORESIS; ENZYMES; GENE ENCODING; GLYCOPROTEINS;

YEAST;

ALPHA 1,6 MANNOSYLTRANSFERASE; BETA N ACETYLHEXOSAMINIDASE A; CELL SURFACE RECEPTOR; GANGLIOSIDE GM2; GENE PRODUCT; GLYCAN DERIVATIVE; GLYCOPROTEIN; HETERODIMER; HISTIDINE; ISOENZYME; MANNOSE 6 PHOSPHATE; MANNOSYLTRANSFERASE; METAL; PROTEIN HEXB; PROTEIN HEXS; RECOMBINANT ENZYME; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ELECTROKINESIS; ENZYME; IMMOBILIZATION; PROTEIN; RECOMBINATION; YEAST;

ALPHA CHAIN; ANTIGENICITY; ARTICLE; BETA CHAIN; CARBOXY TERMINAL SEQUENCE; DEGRADATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME IMMOBILIZATION; ENZYME PURIFICATION; ENZYME REPLACEMENT; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ENZYME SYNTHESIS; FIBROBLAST; FUNGAL GENE; GM2 GANGLIOSIDOSIS; LYSOSOME; LYSOSOME STORAGE DISEASE; MAMMAL CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OGATAEA MINUTA; POLYACRYLAMIDE GEL ELECTROPHORESIS; SANDHOFF DISEASE; TAY SACHS DISEASE; YEAST;

AMINO ACID SEQUENCE; BETA-N-ACETYLHEXOSAMINIDASE; BIOTECHNOLOGY; CELLS, CULTURED; FIBROBLASTS; HUMANS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SACCHAROMYCETALES; SANDHOFF DISEASE; TAY-SACHS DISEASE;

MAMMALIA; PICHIA MINUTA;

EID: 34547819689     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.00463-07     Document Type: Article

References (48)

1. Amalfitano, A., A. J. McVie-Wylie, H. Hu, T. L. Dawson, N. Rabens, P. Plotz, and Y. T. Chen. 1999. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase. Proc. Natl. Acad. Sci. USA 96:8861-8866.
2. Andersson, U., D. Smith, M. Jeyakumar, T. D. Butters, M. C. Bona, R. A. Dwek, and F. M. Platt. 2004. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis. 16:506-515.
3. Asano, N., S. Ishii, H. Kizu, K. Ikeda, K. Yasuda, A. Kato, O. R. Maritn, and J. Q. Fan. 2000. In vivo inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur. J. Biochem. 267:4179-4186.
4. Barton, N. W., R. O. Brady, J. M. Dambrosia, A. M. Di Bisceglie, S. H. Doppelt, S. C. Hill, H. J. Mankin, G. J. Murray, H. I. Parker, and C. E. Argoff. 1991. Replacement therapy for inherited enzyme deficiency- macrophage-medicated glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324:1464-1470.
5. Butters, T. D., R. A. Dwek, and F. M. Platt. 2000. Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders. Chem. Rev. 100:4683-4696.
6. Chen, Y., M. Jin, L. Goodrich, G. Smith, G. Coppola, and D. H. Calhoun. 2000. Purification and characterization of human α-galactosidase A expressed in insect cells using a baculovirus vector. Protein Expr. Purif. 20:228-236.
7. Chen, Y., M. Jin, T. Egborge, G. Coppola, J. Andre, and D. H. Calhoun. 2000. Expression and characterization of glycosylated and catalytically active recombinant human α-galactosidase A produced in Pichia pastoris. Protein Expr. Purif. 20:472-484.
8. Chiba, Y., H. Sakuraba, M. Kotani, R. Kase, K. Kobayashi, M. Takeuchi, S. Ogasawara, Y. Maruyama, T. Nakajima, Y. Takaoka, and Y. Jigami. 2002. Production in yeast of α-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology 12:821-828.
9. Eng, C. M., N. Guffon, W. R. Wilcox, D. P. Germain, P. Lee, S. Waldek, L. Caplan, G. E. Linthrost, and R. J. Desnick. 2001. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345:55-57.
10. Hancock, M. K., D. J. Haskins, G. Sun, and N. M. Dahms. 2002. Identification of residues essential for carbohydrate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol. Chem. 277:11255-11264.
11. Hancock, M. K., R. D. Yammani, and N. M. Dahms. 2002. Localization of the carbohydrate recognition sites of the insulin-like growth factor II/mannose 6-phosphate receptor to domains 3 and 9 of the extracytoplasmic region. J. Biol. Chem. 277:47205-47212.
12. Harmatz, P., C. B. Whitley, L. Waber, R. Pais, R. Steiner, B. Plecko, P. Kaplan, J. Simon, E. Butensky, and J. J. Hopwood. 2004. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. 144:574-580.
13. Hepbildikler, S. T., R. Sandhoff, M. Kolzer, R. L. Proia, and K. Sandhoff. 2002. Physiological substrates for human lysosomal β-hexosaminidase S. J. Biol. Chem. 277:2562-2572.
14. Hoogerbrugge, P. M., B. J. H. M. Poorthuis, A. E. Romme, J. J. P. van de Kamp, G. Wagemaker, and D. W. van Bekkum. 1988. Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse. J. Clin. Investig. 81:1790-1794.
15. Hou, Y., R. Tse, and D. J. Mahuran. 1996. Direct determination of the substrate specificity of the α-active site in heterodimeric β-hexosaminidase A. Biochemistry 35:3963-3969.
16. Ichisaka, S., K. Ohno, I. Yuasa, E. Nanba, H. Sakuraba, and Y. Suzuki. 1998. Increased expression of β-hexosaminidase α chain in cultured skin fibroblasts from patients with carbohydrate-deficient glycoprotein syndrome type I. Brain Dev. 20:302-306.
17. Jung, S. C., I. P. Han, A. Limaye, R. Xu, M. P. Gelderman, P. Zerfas, K. Tirumalai, G. J. Murray, M. J. During, R. O. Brady, and P. Qasba. 2001. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Natl. Acad. Sci. USA 98:2676-2681.
18. Klinge, L., V. Straub, U. Neudorf, and T. Voit. 2005. Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study. Neuropediatrics 36:6-11.
19. Kuroda, K., K. Kobayashi, H. Tsumura, T. Komeda, Y. Chiba, and Y. Jigami. 2006. Production of Man5GlcNAc2-type sugar chain by the methylotrophic yeast Ogataea minuta. FEMS Yeast Res. 6:1052-1062.
20. Kyrkanides, S., J. H. Miller, M. Brouxhon, J. A. Olschowka, and H. J. Federoff. 2005. β-Hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Mol. Brain Res. 133:286-298.
21. Lau, M. M. H., and E. F. Neufeld. 1989. A frameshift mutation in a patient with Tay-Sachs disease causes premature termination and defective intracellular transport of the α-subunit of β-hexosaminidase. J. Biol. Chem. 264:21376-21380.
22. Lemieux, M. J., B. L. Mark, M. M. Cherney, S. G. Withers, D. J. Mahuran, and M. N. G. James. 2006. Crystallographic structure of human β-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. J. Mol. Biol. 359:913-929.
23. Li, S. C., S. Serizawa, and Y. T. Li. 1984. Effect of modification of sialic acid on enzymatic hydrolysis of ganglioside GM1 and GM2. J. Biol. Chem. 259:5409-5410.
24. Little, L. E., M. M. H. Lau, D. V. K. Quon, A. V. Fowler, and E. F. Neufeld. 1988. Proteolytic processing of the α-chain of the lysosomal enzyme, β-hexosaminidase, in normal human fibroblasts. J. Biol. Chem. 263:4288-4292.
25. Maier, T., N. Strater, C. G. Schuette, R. Klingenstein, K. Sandhoff, and W. Saenger. 2003. The X-ray crystal structure of human β-hexosaminidase B provides new insights into Sandhoff disease. J. Mol. Biol. 328:669-681.
26. Mark, B. L., D. J. Mahuran, M. M. Cherney, D. Zhao, S. Knapp, and M. N. G. James. 2003. Crystal structure of human β-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J. Mol. Biol. 327:1093-1109.
27. Meier, E. M., G. Schwarzmann, W. Furst, and K. Sandhoff. 1991. The human GM2 activator protein. J. Biol. Chem. 266:1879-1887.
28. Muenzer, J., J. C. Lamsa, A. Garcia, J. Dacosta, J. Garcia, and D. A. Treco. 2002. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr. Suppl. 91:98-99.
29. Norflus, F., C. J. Tifft, M. P. McDonald, G. Goldstein, J. N. Crawley, A. Hoffmann, K. Sandhoff, K. Suzuki, and R. L. Praia. 1998. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Investig. 101:1881-1888.
30. Odani, T., Y. Shimma, A. Tanaka, and Y. Jigami. 1996. Cloning and analysis of the MNN4 gene required for phosphorylation of N-linked oligosaccharides in Saccharomyces cerevisiae. Glycobiology 6:805-810.
31. Odani, T., Y. Shimma, X. H. Wang, and Y. Jigami. 1997. Mannosylphosphate transfer to cell wall mannan is regulated by the transcriptional level of the MNN4 gene in Saccharomyces cerevisiae. FEBS Lett. 420:186-190.
32. O'Dowd, B. F., M. H. Klavins, H. F. Willard, R. Grabel, J. A. Lowden, and D. J. Mahuran. 1986. Molecular heterogeneity in the infantile and juvenile forms of Sandhoff disease (O-variant GM2 gangliosidosis). J. Biol. Chem. 261:12680-12685.
33. Ohsawa, M., M. Kotani, Y. Tajima, D. Tsuji, Y. Ishibashi, A. Kuraki, K. Itoh, K. Watabe, K. Sango, S. Yamanaka, and H. Sakuraba. 2005. Establishment of immortalized Schwann cells from Sandhoff mice and corrective effect of recombinant human β-hexosaminidase A on the accumulated GM2 ganglioside. J. Hum. Genet. 50:460-467.
34. Potier, M., L. Mameil, M. Belisle, L. Dallaine, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
35. Quon, D. V. K., R. L. Praia, A. V. Fowler, J. Bleibaum, and E. F. Neufeld. 1989. Proteolytic processing of the β-subunit of the lysosomal enzyme, β-hexosaminidase, in normal human fibroblasts. J. Biol. Chem. 264:3380-3384.
36. Reddy, S. T., W. Chai, R. A. Childs, J. D. Page, T. Feizi, and N. M. Dahms. 2004. Identification of a low affinity mannose 6-phosphate-binding site in domain 5 of the cation-independent mannose 6-phosphate receptor. J. Biol. Chem. 279:38658-38667.
37. Sakuraba, H., Y. Chiba, M. Kotani, I. Kawashima, M. Ohsawa, Y. Tajima, Y. Takaoka, Y. Jigami, H. Takahashi, Y. Hirai, T. Shimada, Y. Hashimoto, K. Ishii, T. Kobayashi, K. Watabe, T. Fukushige, and T. Kanzaki. 2006. Corrective effect on Fabry mice of yeast recombinant human α-galactosidase with N-linked sugar chains suitable for lysosomal delivery. J. Hum. Genet. 51:341-352.
38. Schiffmann, R., G. J. Murray, D. Treco, P. Daniel, M. Sellos-Moura, M. Myers, J. M. Quirk, G. C. Zirzow, M. Borowski, K. Loveday, T. Anderson, F. Gillespie, K. L. Oliver, N. O. Jeffries, E. Doo, T. J. Liang, C. Kreps, K. Gunter, K. Frei, K. Crutchfield, R. F. Selden, and R. O. Brady. 2000. Infusion of α-galactosidase A reduces tissue globotriaosylceremide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97:365-370.
39. Stein, C. S., A. Ghodsi, T. Derksen, and B. L. Davidson. 1999. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J. Virol. 73:3424-3429.
40. Takashiba, M., Y. Chiba, and Y. Jigami. 2006. Identification of phosphorylation sites in N-linked glycans by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 78:5208-5213.
41. Tarentino, A. L., and F. Maley. 1972. β-N- Acetylglucosaminidase from hen oviduct. Methods Enzymol. 28:772-776.
42. Trapak, M. B., S. P. Reid, M. Guiral, S. G. Withers, and D. Mahuran. 2004. Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J. Biol. Chem. 279:13478-13487.
43. Tsuji, A., K. Omura, and Y. Suzuki. 1988. Intracellular transport of acid α-glucosidase in human fibroblasts: evidence for involvement of phosphomannosyl receptor-independent system. J. Biochem. 104:276-278.
44. Tsuji, D., A. Kuroki, Y. Ishibashi, T. Itakura, and K. Itoh. 2005. Metabolic correction in microglia derived from Sandhoff disease model mice. J. Neurochem. 94:1631-1638.
45. Van den Hout, J. M. P., J. H. J. Kamphoven, L. P. F. Winkel, W. F. M. Arts, J. B. C. de Klerk, M. C. B. Loonen, A. G. Vulto, A. Cramme-Dijkhuis, N. Weisglas-Kuperus, W. Hop, H. van Hirtum, O. P. van Diggelen, M. Boer, M. A. Kroos, P. A. van Doom, E. van der Voort, B. Sibbles, E. J. J. M. van Corven, J. P. J. Brakenhoff, J. van Hove, J. A. M. Smeitink, G. de Jong, A. J. J. Reuser, and A. T. van der Ploeg. 2004. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics 113:e448-e457.
46. Wraith, J. E., L. A. Clarke, M. Beck, E. H. Kolodny, G. M. Pastores, J. Muenzer, D. M. Rapoport, K. I. Berger, S. J. Sweidler, E. D. Kakkis, T. Braakman, E. Chadbourne, K. Walton-Bowen, and G. F. Cox. 2004. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J. Pediatr. 144:581-588.
47. Yasuda, K., H. H. Chang, H. L. Wu, S. Ishii, and J. Q. Fan. 2004. Efficient and rapid purification of recombinant human α-galacotosidase A by affinity column chromatography. Protein Expr. Purif. 37:499-506.
48. Yuziuk, J. A., C. Bertoni, T. Beccari, A. Orlacchio, Y. Y. Wu, S. C. Li, and Y. T. Li. 1998. Specificity of mouse GM2 activator protein and β-N-acetylhexosaminidases A and B. J. Biol. Chem. 273:66-72.